NCT04941066 (CNF-rumination) is a NA clinical trial of Active neurofeedback in Depression, sponsored by Laureate Institute for Brain Research, Inc..

Who is sponsoring NCT04941066?

NCT04941066 is sponsored by Laureate Institute for Brain Research, Inc..

What drugs are being tested in NCT04941066?

Interventions in NCT04941066: Active neurofeedback, Sham neurofeedback.

What condition does NCT04941066 study?

NCT04941066 studies Depression, Anxiety.

Is NCT04941066 still recruiting?

NCT04941066 is currently completed. Last updated 18 January 2023.

Last reviewed 2023-01-18 · How we verify

NCT04941066: CNF-rumination

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cognitive Process-based Real-time fMRI Neurofeedback in MDD and Rumination

Completed NA Last updated 18 January 2023

What this trial tests

NA trial testing Active neurofeedback in Depression in 44 participants. Completed in 31 March 2022.

Timeline

1 March 2021

Primary endpoint
31 March 2022

31 March 2022

Quick facts

Lead sponsor	Laureate Institute for Brain Research, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	44
Start date	1 March 2021
Primary completion	31 March 2022
Estimated completion	31 March 2022
Sites	1 location across United States

Drugs / interventions tested

Active neurofeedback
Sham neurofeedback

Conditions studied

Depression — all drugs for Depression →
Anxiety — all drugs for Anxiety →

Sponsor

Laureate Institute for Brain Research, Inc.

Who can join

Adults 18 to 65, any sex, with Depression or Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the feasibility and efficacy of real-time fMRI neurofeedback for rumination.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Real-Time fMRI Functional Connectivity Neurofeedback Reducing Repetitive Negative Thinking in Depression: A Double-Blind, Randomized, Sham-Controlled Proof-of-Concept Trial.
Tsuchiyagaito A, Misaki M, Kirlic N, Yu X, et al · · 2023 · cited 21× · PMID 36630946 · DOI 10.1159/000528377
Thalamo-cortical circuits associated with trait- and state-repetitive negative thinking in major depressive disorder.
Tsuchiyagaito A, Misaki M, Cochran G, Philip NS, et al · · 2023 · cited 11× · PMID 37913745 · DOI 10.1016/j.jpsychires.2023.10.058
Whole-brain mechanism of neurofeedback therapy: predictive modeling of neurofeedback outcomes on repetitive negative thinking in depression.
Misaki M, Tsuchiyagaito A, Guinjoan SM, Rohan ML, et al · · 2024 · cited 10× · PMID 39227376 · DOI 10.1038/s41398-024-03066-9
Increased insular functional connectivity during repetitive negative thinking in major depression and healthy volunteers.
Edwards LS, Ganesan S, Tay J, Elliott ES, et al · · 2025 · cited 4× · PMID 40936343 · DOI 10.1017/s0033291725100925
Functional brain network dynamics of brooding in depression: Insights from real-time fMRI neurofeedback.
Ganesan S, Misaki M, Zalesky A, Tsuchiyagaito A. · · 2025 · cited 4× · PMID 40122254 · DOI 10.1016/j.jad.2025.03.121

Verify or expand the search:

Other trials of Active neurofeedback

Trials testing the same drug.

NCT06219681 — Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression · NA · terminated

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Other Laureate Institute for Brain Research, Inc. trials

Trials by the same sponsor.

NCT06410196 — Mood and Decision-making in Methamphetamine Use Disorder · NA · recruiting
NCT06088732 — Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression · Phase 1, PHASE2 · recruiting
NCT06219681 — Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression · NA · terminated
NCT06004115 — Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression · Phase 4 · recruiting
NCT06486584 — Contingency Management for Problematic Behavior Reduction in the Community · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04941066 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laureate Institute for Brain Research, Inc.
Last refreshed: 18 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04941066.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing